-
Phase 2 clinical results of innovative bicyclic peptide therapy to improve vision in patients with diabetic macular edema are positive
Time of Update: 2021-11-05
Recently, Oxurion announced that the THR-149, an investigational therapy jointly developed with Bicycle Therapeutics, has achieved positive results in a phase 2 clinical trial for the treatment of patients with diabetic macular edema (DME) .
-
Brain Science Research: Humans’ Challenge to the “Ultimate Frontier” of Natural Science
Time of Update: 2021-11-05
Scientists recognize that tau is more directly responsible for brain degeneration in Alzheimer’s disease than amyloid, and also confirmed that the recently developed tau-based PET (positron emission tomography) brain imaging technology (tau-PET) can be Accelerate clinical trials for Alzheimer's disease and improve personalized patient treatment .
-
Pfizer's JAK1 inhibitor receives EU CHMP support and is expected to be approved this year for the treatment of atopic dermatitis
Time of Update: 2021-11-05
Abrocitinib is a once-daily oral Janus kinase 1 (JAK1) inhibitor for adult patients with moderate/severe atopic dermatitis (AD) suitable for systemic treatment .
Reference materials:[1] Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis.
-
Treatment significantly prolongs the lives of patients with liver cancer, dual immunocombination therapy reaches the phase 3 clinical endpoint
Time of Update: 2021-11-05
On October 16, AstraZeneca announced that its anti-PD-L1 antibody Imfinzi, in combination with the research anti-CTLA-4 antibody tremelimumab, is in a phase 3 clinical trial for the first-line treatment of patients with unresectable hepatocellular carcinoma Reach the primary endpoint of overall survival .
-
Antibacterial mechanism of "Golden tangerine peel" rich in MMA
Time of Update: 2021-11-05
"Sickness enters from the mouth" refers to bacteria that enter the human intestinal tract through the oral cavity and cause diseases. The culprit food-borne pathogens erode the intestinal epithelial
-
The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally
Time of Update: 2021-11-05
This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.
-
Seeing how deadly viruses invade cells, Chinese and American teams jointly bring new breakthroughs
Time of Update: 2021-11-05
▲Schematic diagram of the combination of LDLRAD3-D1 and VEEV (picture source: reference [1])In subsequent studies, the research team also found clues to change the ability of LDLRAD3-D1 to bind to the virus .
1038/s41586-021-03909-1[2] (2021) Structural basis of Venezuelan equine encephalitis virus engagement of the LDLRAD3 receptor.
-
Can stimulating the "acupoints" of the legs cure diseases?
Time of Update: 2021-11-05
In order to verify the role of Prokr2 neurons, researchers optogenetics and other experimental methods artificially activated Prokr2 expressing neurons, and found that they can simulate the anti-inflammatory effect of electroacupuncture; on the contrary, if this group of neurons is specifically destroyed, it will Let electric acupuncture fail to suppress systemic inflammation .
-
Pioneering algorithm calculates the life expectancy of an individual in good health
Time of Update: 2021-11-05
-Studies have shown that the incidence of chronic diseases is increasing due to unhealthy life>-Experts call on people to pay attention to healthy lifespan (quality of life) and absolute lifespan (num
-
kpNext(TM) Kepe releases new recyclable PET blister film
Time of Update: 2021-11-05
kpNext™ is the only recyclable PET blister film that is fully compatible with existing thermoforming, feeding and heat sealing equipment in the pharmaceutical industry .
kpNext™ is not only the only recyclable PET blister packaging film, but also fully compatible with existing production processes .
-
Subvert the tradition!
Time of Update: 2021-11-05
As part of its "transformation", in order to improve the efficiency of research and development, Covance will also accelerate the digitization of mobile care visits and sample collection to speed up the recruitment of participants and reduce the loss of trial patients .
-
Synrad's Scientific Advisory Committee expands capacity and determines the PI for clinical trials in the United States
Time of Update: 2021-11-05
Beijing, October 13, 2021/PRNewswire/ - Recently, Synerdyne’s scientific advisory committee welcomed 4 world-leading medical experts to join, of which 3 will serve as Synerdyne’s AcoArt under-knee drug-coated balloon (BTK) Registered clinical PI in the United States .
-
New drug for triple negative breast cancer!
Time of Update: 2021-11-05
Gilead recently announced that Health Canada has approved its targeted anticancer drug Trodelvy (sacituzumab govitecan-hziy, gosartuzumab) through the Orbis program (Project Orbis) for the treatment of metastases Adult patients with sexual triple negative breast cancer (mTNBC) .
-
Biocytometer and Envigo jointly promote the sale of severe immunodeficiency B-NDG mouse models
Time of Update: 2021-11-05
The two parties will work together to promote the extensive application of severe immunodeficiency B-NDG mouse models in related research fields .
For more information, please visit EnvigoEnvigo (Envigo RMS LLC) provides a wide range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations .
-
EbioMedicine: Axitinib may effectively reverse the pathological manifestations of Alzheimer's disease
Time of Update: 2021-11-05
Recently, in a research report titled "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics" published in the international journal EbioMedicine, scientists from the University of British Columbia and other institutions found through research that A drug commonly used to treat cancer may help restore memory and cognitive functions in mice that show symptoms of Alzheimer's disease .
-
This disease affects approximately 280 million people worldwide. RNAi therapy provides new treatment ideas
Time of Update: 2021-11-05
Reference materials:[1] Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder.
-
Bicyclic peptide accurately delivers cytotoxic drugs to treat bladder cancer and ovarian cancer, clinical results are positive
Time of Update: 2021-11-05
Bicycle Therapeutics today announced that two new-generation bicyclic peptide-conjugated toxins have shown positive anti-cancer activity in phase 1 clinical trials .
Among them, the bicyclic peptide-conjugated toxin BT5528 targeting EphA2 allowed two patients with urothelial cancer to obtain partial remission, reaching 80% disease control rate in ovarian cancer patients .
-
The world's first ALL CAR-T cell therapy!
Time of Update: 2021-11-05
Tecartus received accelerated approval from the US FDA in July 2020 for the treatment of relapsed or refractory mantle cell lymphoma (R/R MCL) adults who had previously received 2 or more systemic therapies (including a BTK inhibitor) Patient .
-
Merck's Keytruda second-line therapy for liver cancer successfully confirmed Phase III study
Time of Update: 2021-11-05
Therefore, in late April of this year, the FDA Oncology Drug Advisory Committee organized a three-day meeting to specifically discuss 6 adaptations that some PD-1/PD-L1 drugs were marketed in the form of "accelerated approval" but failed in confirmatory clinical trials In order to decide whether to keep it on the market, the indications for Keytruda's second-line treatment of hepatocellular carcinoma are covered .
-
BeiGene announced that Baiyueze(R) (Zebutinib) was approved for the treatment of mantle cell lymphoma
Time of Update: 2021-11-05
At present, Baiyueze has been approved for the treatment of mantle cell lymphoma in 9 countries Beijing, China, Sydney, Australia and Cambridge, Massachusetts, October 11, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) is a global company based on science A biotechnology company that focuses on the development and commercialization of innovative drugs worldwide .
